Date: 2015-02-05
Type of information: Private placement
Company: Bind Therapeutics (USA - MA)
Investors:
Amount: $21.5 million
Funding type: private placement
Planned used:
Others: * On February 5, 2015, Bind Therapeutics announced the pricing of its underwritten public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consists of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share. All units in the offering are to be sold by Bind. The gross proceeds to BIND from this offering are expected to be approximately $21.5 million, not including any future proceeds from the exercise of the warrants.
* On February 4, 2015, Bind Therapeutics announced that it is commencing an underwritten public offering of units consisting of shares of Bind's common stock and warrants to purchase shares of BIND's common stock. Cowen and Company and Stifel are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and Oppenheimer & Co. is acting as co-manager for the offering.
Therapeutic area: Cancer - Oncology
